17-Mar-2026
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Fri, 13-Mar 7:41 AM ET)
TipRanks (Fri, 13-Mar 2:02 AM ET)
Foothill Regional Medical Center Receives 2026 Patient Safety Excellence Award from Healthgrades
PRNewswire (Wed, 11-Mar 8:00 AM ET)
ASTH to Spotlight AI-Driven Care Model at Five Major Investor Conferences in March
Market Chameleon (Wed, 4-Mar 4:30 AM ET)
Astrana Health, Inc. to Participate in Upcoming Investor Conferences
PRNewswire (Tue, 3-Mar 5:00 PM ET)
Market Chameleon (Mon, 2-Mar 6:14 AM ET)
Astrana Health, Inc. Reports Fourth Quarter and Year End 2025 Results
PRNewswire (Mon, 2-Mar 7:00 AM ET)
PRNewswire (Mon, 26-Jan 8:00 AM ET)
Astrana Health, Inc. to Participate in Upcoming Investor Conference
PRNewswire (Tue, 6-Jan 8:08 AM ET)
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Astrana Health trades on the NASDAQ stock market under the symbol ASTH.
As of March 17, 2026, ASTH stock price climbed to $24.80 with 350,459 million shares trading.
ASTH has a beta of 0.74, meaning it tends to be less sensitive to market movements. ASTH has a correlation of 0.04 to the broad based SPY ETF.
ASTH has a market cap of $1.38 billion. This is considered a Small Cap stock.
Last quarter Astrana Health reported $951 million in Revenue and $.54 earnings per share. This beat revenue expectation by $23 million and exceeded earnings estimates by $.28.
The top ETF exchange traded funds that ASTH belongs to (by Net Assets): IJR, VTI, IWM, VB, IJS.
ASTH has underperformed the market in the last year with a return of -19.0%, while SPY returned +19.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ASTH shares. However, ASTH has outperformed the market in the last 3 month and 2 week periods, returning +9.5% and +1.2%, while SPY returned +0.2% and -1.4%, respectively. This indicates ASTH has been having a stronger performance recently.
ASTH support price is $23.73 and resistance is $25.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASTH shares will trade within this expected range on the day.
